The T790M mutation is crucial because it modifies the approach to treatment. Patients with this mutation often experience a relapse after an initial response to EGFR TKIs. Identifying the presence of T790M can guide oncologists to switch treatment strategies, often opting for third-generation TKIs like osimertinib, which are designed to overcome this specific resistance.
